ArticleCardiovascular & hematological agents in medicinal chemistry2026
Administration of Aspirin and Aqueous Leaf Extract of
Article in Cardiovascular & hematological agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeucocytosis, inflammation, and thrombocytosis are major risk factors for diabetes mellitus. This study investigates the effects of administering aspirin, meloxicam, or Terminalia catappa leaf extract on leucocyte count and platelet indices in rats with Diabetes Mellitus (DM).
methodsMale Wistar rats were randomly assigned to seven groups of six rats each. The control group received 5 ml/kg of distilled water orally, while the DM was induced with 150 mg/Kg alloxan. The DM+ Terminalia catappa (TC) group was administered 130 mg/kg, while the DM+Aspirin and DM+Meloxicam groups were administered aspirin (30 mg/kg) and meloxicam (2 mg/kg) orally, respectively. DM+TC+Aspirin and DM+TC+Meloxicam groups received Terminalia catappa in addition to aspirin and meloxicam, respectively, for 14 days.
resultsTotal WBC, neutrophil and eosinophil counts, tumour necrosis factor-α and interleukin-6 increased significantly (p <0.05), while lymphocytes, monocytes, platelet counts, and platelet indices decreased significantly (p <0.05) in the diabetic group. The raised parameters were significantly (p <0.05) reduced by aspirin, meloxicam, and Terminalia catappa extract compared with the diabetic control group. They were also significantly (p <0.05) reduced in DM-treated with extract and aspirin. Platelet counts and MPV were raised (p < 0.05) in the T. catappa, aspirin, and meloxicam + extract groups compared to the control and diabetic groups. DISCUSSION: T. catappa extract and aspirin ameliorated inflammation due to their active phytochemicals.
conclusionExtract of Terminalia catappa, in combination with aspirin, reduced WBC count but increased platelet indices. This indicates the potential of the extract to reduce inflammation in diabetes mellitus, but with the risk of thrombocytosis.
Indexed as
Identifiers
42083944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.